Ernexa Therapeutics Inc.
ERNA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $9,049 | $9,529 | $142,474 | $226,612 |
| - Cash | $3,047 | $4,315 | $1,918 | $1,729 |
| + Debt | $552 | $593 | $2,882 | $684 |
| Enterprise Value | $6,554 | $5,807 | $143,438 | $225,567 |
| Revenue | $0 | $0 | $0 | $1 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | $0 | $0 | $1 |
| % Margin | – | – | – | 100% |
| EBITDA | -$1,186 | -$2,446 | -$2,661 | -$2,197 |
| % Margin | – | – | – | -219,700% |
| Net Income | -$1,240 | -$3,139 | -$8,202 | -$5,759 |
| % Margin | – | – | – | -575,900% |
| EPS Diluted | -0.15 | -0.61 | -0.15 | -0.42 |
| % Growth | 75.4% | -306.7% | 64.3% | – |
| Operating Cash Flow | -$1,272 | -$2,532 | -$2,065 | -$3,545 |
| Capital Expenditures | -$22 | $0 | $0 | $0 |
| Free Cash Flow | -$1,294 | -$2,532 | -$2,065 | -$3,545 |